Loading...
NASDAQ: REGN
Regeneron Pharmaceuticals, Inc.
Healthcare · Biotechnology
●S&P 500 since 2013
Market Cap
$77.07B
52w High
$821.11
52w Low
$476.49
P/E
16.94
Volume
59.39K
Outstanding Shares
103.90M
Company profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
CEOLeonard S. Schleifer
SectorHealthcare
IndustryBiotechnology
Employees15,158
IPO dateApr 2, 1991
Valuation
Forward P/E—
EV/EBITDA13.81
Enterprise value$80.33B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth2.51%
Gross margin85.35%▼0.90%vs FY2024
Operating margin24.95%▼11.22%vs FY2024
ROE14.41%▼4.12%vs FY2024
Analyst consensus
RatingBuy
Target price$862.74▲16.31%
34
Buy
14
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$12.89
$8.43
Q3FY25
ActualEst.
$11.83
$9.65
Q4FY25
ActualEst.
$11.44
$10.74
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$3.68B
$3.29B
Q3FY25
ActualEst.
$3.75B
$3.59B
Q4FY25
ActualEst.
$3.88B
$3.81B
Q1FY26
Next Est.
—